Insider Trading Activity Akebia Therapeutics, Inc. (NASDAQ:AKBA) – SVP Sold 5,000 shares of Stock

ME Staff

7 years ago

Insider Trading Activity For Akebia Therapeutics, Inc. (NASDAQ:AKBA)

Michel Dahan , SVP of Akebia Therapeutics, Inc. (NASDAQ:AKBA) reportedly Sold 5,000 shares of the company’s stock at an average price of 15 for a total transaction amount of $75,000.00 SEC Form

Insider Trading History For Akebia Therapeutics, Inc. (NASDAQ:AKBA)

On 3/25/2014 Muneer A Satter, Director, bought 91,295 with an average share price of $17.00 per share and the total transaction amounting to $1,552,015.00.View SEC Filing

On 3/25/2014 John P Butler, CEO, bought 13,850 with an average share price of $17.00 per share and the total transaction amounting to $235,450.00.View SEC Filing

On 3/25/2014 Jason Amello, CFO, bought 4,000 with an average share price of $17.00 per share and the total transaction amounting to $68,000.00.View SEC Filing

On 3/25/2014 A/S Novo, Insider, bought 182,590 with an average share price of $17.00 per share and the total transaction amounting to $3,104,030.00.View SEC Filing

On 11/12/2014 Muneer A Satter, Director, bought 5,000 with an average share price of $11.90 per share and the total transaction amounting to $59,500.00.View SEC Filing

On 11/12/2014 John P Butler, CEO, bought 1,000 with an average share price of $10.31 per share and the total transaction amounting to $10,310.00.View SEC Filing

On 11/13/2014 Muneer A Satter, Director, bought 5,000 with an average share price of $11.56 per share and the total transaction amounting to $57,800.00.View SEC Filing

Analyst Ratings For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
These are 5 Buy Ratings .
The current consensus rating for Akebia Therapeutics, Inc. (NASDAQ:AKBA) is Buy (Score: 3.00) with a consensus target price of $21.80 , a potential (45.14% upside)

Analyst Ratings History For Akebia Therapeutics, Inc. (NASDAQ:AKBA)

On 3/9/2016 J P Morgan Chase & Co Lower Price Target of rating Market Outperform with a price target of $24.00 to $16.00
On 5/8/2016 Morgan Stanley Reiterated Rating Buy
On 8/9/2016 Credit Suisse Group Reiterated Rating Hold with a price target of $8.00
On 9/29/2016 Brean Capital Initiated Coverage of rating Buy with a price target of $18.00
On 4/26/2017 JMP Securities Boost Price Target of rating Outperform with a price target of $19.00 to $21.00
On 5/17/2017 Needham & Company LLC Reiterated Rating Buy with a price target of $18.00 to $21.00
On 6/30/2017 Aegis Reiterated Rating Buy

Recent Trading Activity for Akebia Therapeutics, Inc. (NASDAQ:AKBA)
Shares of Akebia Therapeutics, Inc. closed the previous trading session at 15.02 down -0.23 -1.51% with 306,168 shares trading hands.